The Patent Finder
SR

Scholar Rock, Inc.

First filing 2015
OverviewNotableFeesChangesFamiliesPatent listSources & methods

34 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in May 2034. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2034
Next term end
13
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compositions and Methods for Growth Factor Modulation US 10,597,443
Cited by 41 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Ends May 2034 · Low confidence
Also notable
Methods for Inhibiting Myostatin Activation by Administering Anti-Pro/Latent Myostatin Antibodies US 10,287,345
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Ends Sep 2036 · Medium confidence
Also notable
Anti-Pro/Latent-Myostatin Antibodies and Uses Thereof US 10,307,480
Cited by 18 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Ends Nov 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 28, 2027
    The maintenance fee for Compositions and Methods for Growth Factor Modulation (US 11,827,698) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 2 fees due Sep 12 to 24, 2027 · next Sep 12

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,399,676Compositions and Methods for Growth Factor Modulation
In force
 · Medium confidence
In forceMedium confidence
US 9,573,995Compositions and Methods for Growth Factor Modulation
In force
 · Medium confidence
In forceMedium confidence
US 9,580,500Compositions and Methods for Growth Factor Modulation
In force
 · Medium confidence
In forceMedium confidence
US 9,758,576Compositions and Methods for Growth Factor Modulation
In force
 · Low confidence
In forceLow confidence
US 9,758,577Compositions and Methods for Growth Factor Modulation
In force
 · Low confidence
In forceLow confidence
US 10,597,443Compositions and Methods for Growth Factor Modulation
In force
 · Low confidence
In forceLow confidence
US 10,981,981Compositions and Methods for Growth Factor Modulation
In force
 · Medium confidence
In forceMedium confidence
US 11,827,698Compositions and Methods for Growth Factor Modulation
In force
 · Low confidence
In forceLow confidence
US 12,454,570Compositions and Methods for Growth Factor Modulation
In force
 · Low confidence
In forceLow confidence
US 12,577,296Compositions and Methods for Growth Factor Modulation
In force
 · Medium confidence
In forceMedium confidence
10 of 34 patents shown.
Pro members see all 34.
Pro members: see all 34 patents
Also on record, not counted in the 34: 21 applications pending · 15 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited